{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:27:23Z","timestamp":1793388443500,"version":"4.5.0"},"reference-count":134,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurodegenerative disorders (NDs) represent a group of different diseases characterized by the progressive degeneration and death of the nervous system\u2019s cells. The diagnosis is challenging, especially in the early stages, due to no specific clinical signs and symptoms. In this context, laboratory medicine could support clinicians in detecting and differentiating NDs. Indeed, biomarkers could indicate the pathological mechanisms underpinning NDs. The ideal biofluid for detecting the biomarkers of NDs is cerebrospinal fluid (CSF), which has limitations, hampering its widespread use in clinical practice. However, intensive efforts are underway to introduce high-sensitivity analytical methods to detect ND biomarkers in alternative nonivasive biofluid, such as blood or saliva. This study presents an overview of the ND molecular biomarkers currently used in clinical practice. For some diseases, such as Alzheimer\u2019s disease or multiple sclerosis, biomarkers are well established and recommended by guidelines. However, for most NDs, intensive research is ongoing to identify reliable and specific biomarkers, and no consensus has yet been achieved.<\/jats:p>","DOI":"10.3390\/ijms25084323","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:24:26Z","timestamp":1713176666000},"page":"4323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice"],"prefix":"10.3390","volume":"25","author":[{"given":"Luisa","family":"Agnello","sequence":"first","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Maria","family":"Gambino","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, University Hospital \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Internal Medicine and Medical Specialties \u201cG. D\u2019Alessandro\u201d, Department of Health Promotion, Maternal and Infant Care, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Masucci","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tamburello","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Scazzone","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Lo Sasso","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, University Hospital \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-9041","authenticated-orcid":false,"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy"},{"name":"Department of Laboratory Medicine, University Hospital \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lamptey, R.N.L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., and Singh, J. (2022). A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031851"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"952161","DOI":"10.3389\/fpubh.2022.952161","article-title":"Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990\u20132019","volume":"10","author":"Ding","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e202300225","DOI":"10.1002\/slct.202300225","article-title":"Neurodegenerative Diseases: Their Onset, Epidemiology, Causes and Treatment","volume":"8","author":"Zaib","year":"2023","journal-title":"ChemistrySelect"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-12-802395-2.00021-3","article-title":"Concepts and classification of neurodegenerative diseases","volume":"145","author":"Kovacs","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","article-title":"Microtubule-associated protein tau in development, degeneration and protection of neurons","volume":"85","author":"Wang","year":"2008","journal-title":"Prog. Neurobiol"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kova\u010d, V., and \u010curin \u0160erbec, V. (2022). Prion Protein: The Molecule of Many Forms and Faces. Int. J. Mol. Sci, 23.","DOI":"10.3390\/ijms23031232"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp. Mol. Med"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jalz.2019.06.3916","article-title":"Profound degeneration of wake-promoting neurons in Alzheimer\u2019s disease","volume":"15","author":"Oh","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_12","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health, 7, e105\u2013e125."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fpsyt.2012.00026","article-title":"A Peephole into the Brain: Neuropathological Features of Alzheimer\u2019s Disease Revealed by in vivo Two-Photon HardyImaging","volume":"3","author":"Liebscher","year":"2012","journal-title":"Front. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: An updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_17","first-page":"507","article-title":"Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer\u2019s Disease","volume":"9","author":"Cohen","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ene.14117","article-title":"Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients","volume":"27","author":"Boccardi","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_20","first-page":"371","article-title":"Diagnosis of Early Alzheimer\u2019s Disease: Clinical Practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13195-020-00696-1","article-title":"Cerebrospinal fluid A\u03b21-40 peptides increase in Alzheimer\u2019s disease and are highly correlated with phospho-tau in control individuals","volume":"12","author":"Lehmann","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"ref_24","first-page":"4942562","article-title":"Physician practice patterns associated with diagnostic evaluation of patients with suspected mild cognitive impairment and Alzheimer\u2019s disease","volume":"2019","author":"Judge","year":"2019","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e057528","DOI":"10.1002\/alz.057528","article-title":"Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease: An international overview","volume":"17","author":"Delaby","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-023-01188-8","article-title":"Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer\u2019s disease diagnosis in a memory clinic cohort","volume":"15","author":"Hirtz","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_30","first-page":"51","article-title":"Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer\u2019s disease pathology","volume":"7","author":"Nadal","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Saunders, T., Gunn, C., Blennow, K., Kvartsberg, H., Zetterberg, H., Shenkin, S.D., Cox, S.R., Deary, I.J., Smith, C., and King, D. (2023). Neurogranin in Alzheimer\u2019s disease and ageing: A human post-mortem study. Neurobiol. Dis., 177.","DOI":"10.1016\/j.nbd.2023.105991"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/00207454.2021.1881087","article-title":"The synaptic marker neurogranin as a disease state biomarker in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"132","author":"Wang","year":"2022","journal-title":"Int. J. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/labmed\/lmaa062","article-title":"Neurogranin as a Novel Biomarker in Alzheimer\u2019s Disease","volume":"52","author":"Agnello","year":"2021","journal-title":"Lab. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Agnello, L., Lo Sasso, B., Vidali, M., Scazzone, C., Piccoli, T., Gambino, C.M., Bivona, G., Giglio, R.V., Ciaccio, A.M., and La Bella, V. (2021). Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer\u2019s Disease. Diagnostics, 11.","DOI":"10.3390\/diagnostics11122339"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Piccoli, T., Blandino, V., Maniscalco, L., Matranga, D., Graziano, F., Guajana, F., Agnello, L., Lo Sasso, B., Gambino, C.M., and Giglio, R.V. (2022). Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer\u2019s Disease from Other Neurological Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810831"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31083\/j.jin2204085","article-title":"Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer\u2019s Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis","volume":"22","author":"Fan","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sahrai, H., Norouzi, A., Hamzehzadeh, S., Majdi, A., Kahfi-Ghaneh, R., and Sadigh-Eteghad, S. (2023). SIMOA-based analysis of plasma NFL levels in MCI and AD patients: A systematic review and meta-analysis. BMC Neurol., 23.","DOI":"10.1186\/s12883-023-03377-2"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Antonioni, A., Raho, E.M., Lopriore, P., Pace, A.P., Latino, R.R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., and Pugliatti, M. (2023). Frontotemporal Dementia, Where Do We Stand? A Narrative Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411732"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1002\/alz.13363","article-title":"Frontotemporal dementia: Past, present, and future","volume":"19","author":"Ulugut","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jnc.13588","article-title":"Molecular neuropathology of frontotemporal dementia: Insights into disease mechanisms from postmortem studies","volume":"138","author":"Mackenzie","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/21678421.2017.1281962","article-title":"Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival","volume":"18","author":"Mattsson","year":"2017","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson\u2019s Disease in 204 Countries\/Territories From 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","article-title":"When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients","volume":"85","author":"Koga","year":"2015","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-Synuclein as a Biomarker of Parkinson\u2019s Disease: Good, but Not Good Enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","article-title":"Differential role of CSF alpha-synuclein species, tau, and A\u03b242 in Parkinson\u2019s Disease","volume":"6","author":"Parnetti","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: The Parkinson\u2019s Progression Markers Initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","article-title":"In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"638718","DOI":"10.3389\/fnagi.2021.638718","article-title":"Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein","volume":"13","author":"Abdi","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","article-title":"Fluid and Biopsy Based Biomarkers in Parkinson\u2019s Disease","volume":"20","author":"Coughlin","year":"2023","journal-title":"Neurotherapeutics."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: A meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson\u2019s from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease","volume":"36","author":"Aamodt","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00702-023-02632-7","article-title":"Blood neurofilament light chain in Parkinson\u2019s disease","volume":"130","author":"Buhmann","year":"2023","journal-title":"J. Neural. Transm."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Liu, T.W., Chen, C.M., and Chang, K.H. (2022). Biomarker of Neuroinflammation in Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084148"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: An update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Foska, A., Tsantzali, I., Sideri, E., Stefanou, M.I., Bakola, E., Kitsos, D.K., Zompola, C., Bonakis, A., Giannopoulos, S., and Voumvourakis, K.I. (2022). Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. Medicina, 58.","DOI":"10.3390\/medicina58050612"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1533317519869700","article-title":"Cerebrospinal Fluid, Imaging, and Physiological Biomarkers in Dementia With Lewy Bodies","volume":"34","author":"Mavroudis","year":"2019","journal-title":"Am J Alzheimer\u2019s Dis Other Demen."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","article-title":"Creutzfeldt-Jakob disease: A systematic review of global incidence, prevalence, infectivity, and incubation","volume":"20","author":"Uttley","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1072952","DOI":"10.3389\/fneur.2023.1072952","article-title":"Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease","volume":"14","author":"Senesi","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/19336896.2024.2311950","article-title":"A systemic analysis of Creutzfeldt Jakob disease cases in Asia","volume":"18","author":"Rasheed","year":"2024","journal-title":"Prion"},{"key":"ref_68","unstructured":"Sitammagari, K.K., and Masood, W. (2024). StatPearls, StatPearls."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/WNL.0b013e318263565f","article-title":"A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease","volume":"79","author":"Hamlin","year":"2012","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00401-017-1683-0","article-title":"Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: Diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A\u03b242 levels","volume":"133","author":"Lattanzio","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_71","first-page":"1471","article-title":"Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and A\u03b242 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer\u2019s Disease with Emphasis on Atypical Disease Variants","volume":"55","author":"Lattanzio","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1007\/s12035-016-0128-4","article-title":"Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: Over 10-Year Period Review","volume":"54","author":"Koscova","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fnagi.2017.00289","article-title":"Cerebrospinal Fluid Biomarkers of Alzheimer\u2019s Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia","volume":"9","author":"Llorens","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jocn.2018.01.064","article-title":"CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt-Jakob disease diagnosis while transitioning to next generation diagnostics","volume":"50","author":"Li","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-019-09537-0","article-title":"Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC","volume":"266","author":"Baiardi","year":"2019","journal-title":"J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-021-00815-6","article-title":"Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease","volume":"13","author":"Zerr","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Llorens, F., Villar-Piqu\u00e9, A., Hermann, P., Schmitz, M., Calero, O., Stehmann, C., Sarros, S., Moda, F., Ferrer, I., and Poleggi, A. (2020). Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease. Biomolecules, 10.","DOI":"10.3390\/biom10020290"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","article-title":"Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease","volume":"20","author":"Hermann","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/1673-5374.200794","article-title":"Current view and perspectives in amyotrophic lateral sclerosis","volume":"12","author":"Mathis","year":"2017","journal-title":"Neural. Regen. Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Duranti, E., and Villa, C. (2022). Molecular Investigations of Protein Aggregation in the Pathogenesis of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010704"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40246-023-00479-3","article-title":"Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis","volume":"17","author":"Li","year":"2023","journal-title":"Hum. Genom."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Le Gall, L., Anakor, E., Connolly, O., Vijayakumar, U.G., Duddy, W.J., and Duguez, S. (2020). Molecular and Cellular Mechanisms Affected in ALS. J. Pers. Med., 10.","DOI":"10.1186\/s13395-020-00238-1"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ane.13698","article-title":"Blood biomarkers in ALS: Challenges, applications and novel frontiers","volume":"146","author":"Sturmey","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.clinph.2020.04.005","article-title":"A proposal for new diagnostic criteria for ALS","volume":"131","author":"Shefner","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"ref_85","first-page":"176","article-title":"Diagnosing ALS: The Gold Coast criteria and the role of EMG","volume":"22","author":"Turner","year":"2022","journal-title":"Pract. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jnnp-2021-327129","article-title":"Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS","volume":"93","author":"Halbgebauer","year":"2022","journal-title":"J. Neurol. Neurosurg Psychiatry."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"753242","DOI":"10.3389\/fnagi.2021.753242","article-title":"Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study","volume":"13","author":"Vacchiano","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/ene.14789","article-title":"Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis","volume":"28","author":"Agnello","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","article-title":"Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis","volume":"24","author":"Magen","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"663637","DOI":"10.3389\/fneur.2021.663637","article-title":"TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40263-021-00887-w","article-title":"Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment","volume":"36","author":"Jakimovski","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_92","first-page":"259","article-title":"Multiple sclerosis: Pregnancy and women\u2019s health issues","volume":"34","year":"2019","journal-title":"Neurologia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1001\/jama.2022.14236","article-title":"What Is Multiple Sclerosis?","volume":"328","author":"Marcus","year":"2022","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis, a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2021.10.004","article-title":"Laboratory biomarkers of Multiple Sclerosis (MS)","volume":"99","author":"Arneth","year":"2022","journal-title":"Clin. Biochem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M5-4","article-title":"Polyclonal free light chains: A biomarker of inflammatory disease or treatment target?","volume":"5","author":"Brebner","year":"2013","journal-title":"F1000 Med. Rep."},{"key":"ref_99","first-page":"2303857","article-title":"Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis","volume":"2016","author":"Passerini","year":"2016","journal-title":"Mult. Scler. Int."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Crespi, I., Vecchio, D., Serino, R., Saliva, E., Virgilio, E., Sulas, M.G., Bellomo, G., Dianzani, U., Cantello, R., and Comi, C. (2019). K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040446"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fimmu.2019.00641","article-title":"CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort","volume":"10","author":"Senel","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis","volume":"25","author":"Siller","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","article-title":"Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis","volume":"72","author":"Mowry","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1007\/s11033-011-1441-7","article-title":"Circulating microRNAs involved in multiple sclerosis","volume":"39","author":"Siegel","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1352458513496343","article-title":"Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing","volume":"20","author":"Keller","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and Incidence of Huntington\u2019s Disease: An Updated Systematic Review and Meta-Analysis","volume":"37","author":"Medina","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","article-title":"Biofluid Biomarkers in Huntington\u2019s Disease","volume":"1780","author":"Rodrigues","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Morena, E., Romano, C., Marconi, M., Diamant, S., Buscarinu, M.C., Bellucci, G., Romano, S., Scarabino, D., Salvetti, M., and Ristori, G. (2023). Peripheral Biomarkers in Manifest and Premanifest Huntington\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076051"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"fcac309","DOI":"10.1093\/braincomms\/fcac309","article-title":"Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity","volume":"4","author":"Caron","year":"2022","journal-title":"Brain. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1038\/s41380-023-02230-9","article-title":"Tau: A biomarker of Huntington\u2019s disease","volume":"28","author":"Lepinay","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","article-title":"Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation","volume":"22","author":"Bissel","year":"2012","journal-title":"Brain. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M.M., Painuli, S., Semwal, P., Wilairatana, P., and Mubarak, M.S. (2022). Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases. Molecules, 27.","DOI":"10.3390\/molecules27103194"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014Aliterature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Aragon-Gawinska, K., Mouraux, C., Dangouloff, T., and Servais, L. (2023). Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review. Genes, 14.","DOI":"10.3390\/genes14071377"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J. Child. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Pino, M.G., Rich, K.A., and Kolb, S.J. (2021). Update on Biomarkers in Spinal Muscular Atrophy. Biomark. Insights, 16.","DOI":"10.1177\/11772719211035643"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Bayoumy, S., Verberk, I.M.W., Vermunt, L., Willemse, E., den Dulk, B., van der Ploeg, A.T., Pajkrt, D., Nitz, E., van den Hout, J.M.P., and van der Post, J. (2024). Neurofilament light protein as a biomarker for spinal muscular atrophy: A review and reference ranges. Clin. Chem. Lab. Med.","DOI":"10.1515\/cclm-2023-1311"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/mus.21350","article-title":"An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy","volume":"40","author":"Elsheikh","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_126","unstructured":"Adam, M.P. (1998). GeneReviews\u00ae, University of Washington."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: Opportunities and challenges","volume":"8","author":"Brooker","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-019-1013-9","article-title":"Guidelines on the diagnosis and management of the progressive ataxias","volume":"14","author":"Greenfield","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","article-title":"Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3","volume":"14","author":"Li","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e11803","DOI":"10.15252\/emmm.201911803","article-title":"Neurofilaments in spinocerebellar ataxia type 3: Blood biomarkers at the preataxic and ataxic stage in humans and mice","volume":"12","author":"Wilke","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12311-022-01507-z","article-title":"Association Between Serum Neurofilament Light Chain and Neurochemistry Deficits in Patients with Spinocerebellar Ataxia Type 3","volume":"23","author":"Chen","year":"2024","journal-title":"Cerebellum"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"13517","DOI":"10.1038\/s41598-021-92855-z","article-title":"Serum neurofilament light chain as a severity marker for spinocerebellar ataxia","volume":"11","author":"Shin","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/alz.12545","article-title":"Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease: An international overview","volume":"18","author":"Delaby","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:36Z","timestamp":1760106456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":134,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25084323"],"URL":"https:\/\/doi.org\/10.3390\/ijms25084323","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]}}}